Status:
COMPLETED
HD10 for Early Stages
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin´s Lymphoma
Eligibility:
All Genders
16-75 years
Phase:
PHASE3
Brief Summary
This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to ...
Eligibility Criteria
Inclusion
- Hodgkin´s lymphoma (histologically proven)
- CS (PS) IA, IB, IIA,IIB without any of the following risk factors:
- bulky mediastinal mass (\> 1/3 maximum transverse thorax diameter)
- extranodal involvement
- ESR \> 50 (A), \> 30 (B-symptoms)
- 3 or more lymph node areas involved
- written informaed consent
Exclusion
- Leukocytes \<3000/microl
- Platelets \<100000/microl
- Hodgkin´s Disease as "composite lymphoma"
- Activity index (WHO) \< grade 2
Key Trial Info
Start Date :
May 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1370 Patients enrolled
Trial Details
Trial ID
NCT00265018
Start Date
May 1 1998
Last Update
July 29 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.